Richard Buller Sells 9,000 Shares of Celcuity (NASDAQ:CELC) Stock

Key Points

• Director Richard Buller sold 9,000 shares on May 4 at an average price of $140.46 for proceeds of $1,264,140, reducing his ownership by 57.11% to 6,760 shares; the sale was executed under a pre‑arranged Rule 10b5‑1 trading plan.
• Celcuity reported a major clinical win — Phase‑III gedatolisib outperformed Novartis’ Piqray and showed a survival benefit in PIK3CA+ metastatic breast cancer — a catalyst that has driven buying, analyst upgrades and takeover speculation.
• Shares traded near $139.44 with a market cap of about $6.74B after a roughly 13x one‑year surge; the consensus from analysts is a Moderate Buy with an average price target of $134.50, though opinions and near‑term valuation concerns are mixed.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) Director Richard Buller sold 9,000 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the transaction, the director directly owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Celcuity Price Performance

Celcuity stock traded down $2.25 during midday trading on Wednesday, reaching $139.44. The company had a trading volume of 801,530 shares, compared to its average volume of 798,960. The company has a market capitalization of $6.74 billion, a P/E ratio of -36.79 and a beta of 0.09. Celcuity, Inc. has a 12-month low of $9.51 and a 12-month high of $151.02. The firm's fifty day simple moving average is $115.27 and its 200-day simple moving average is $103.28. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.09. As a group, equities analysts anticipate that Celcuity, Inc. will post -3.97 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on CELC shares. Citizens Jmp raised their target price on shares of Celcuity from $150.00 to $160.00 and gave the stock a "market outperform" rating in a research note on Monday. Citigroup reissued an "outperform" rating on shares of Celcuity in a research note on Monday. Wall Street Zen lowered shares of Celcuity from a "hold" rating to a "sell" rating in a research note on Saturday, April 25th. Stifel Nicolaus set a $150.00 target price on shares of Celcuity in a research note on Monday. Finally, Craig Hallum reissued a "buy" rating and issued a $189.00 target price on shares of Celcuity in a research note on Monday. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Celcuity has a consensus rating of "Moderate Buy" and an average price target of $134.50.

Trending Headlines about Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Phase‑III headline: gedatolisib outperformed Novartis’ Piqray and showed a survival benefit in PIK3CA+ metastatic breast cancer — the clinical win is the primary fundamental catalyst that drove recent buying and acquisition speculation. Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3
• Positive Sentiment: Analyst support: Guggenheim reiterated a Buy and other firms (Needham) issued positive forecasts and price‑target increases, reinforcing investor confidence and fueling takeover chatter. Guggenheim Keeps Their Buy Rating on Celcuity (CELC) Needham & Company LLC Issues Positive Forecast for Celcuity
• Neutral Sentiment: Valuation debate: commentary asks whether a ~13x one‑year surge leaves meaningful upside from here — this frames mixed investor sentiment despite the clinical win. Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?
• Negative Sentiment: Near‑term estimate trims: HC Wainwright slightly lowered Q1–Q3/Q2 2026 EPS forecasts (small downgrades) — a signal that near‑term cash burn, timing of revenues or costs could be risk factors even as they lift long‑term projections. (Research note released 5/4/2026)
• Negative Sentiment: Technical/profit‑taking pressure: stock is trading near its 1‑year high after a rapid rally; modestly elevated volume and the high headline valuation increase the odds of short‑term pullbacks as some investors lock in gains.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Creative Planning acquired a new stake in shares of Celcuity during the 2nd quarter worth approximately $177,000. Rhumbline Advisers increased its holdings in shares of Celcuity by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company's stock worth $570,000 after buying an additional 503 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Celcuity during the 2nd quarter worth approximately $169,000. Quantinno Capital Management LP increased its holdings in shares of Celcuity by 20.7% during the 2nd quarter. Quantinno Capital Management LP now owns 243,042 shares of the company's stock worth $3,245,000 after buying an additional 41,756 shares during the last quarter. Finally, Paloma Partners Management Co increased its holdings in shares of Celcuity by 285.8% during the 2nd quarter. Paloma Partners Management Co now owns 82,137 shares of the company's stock worth $1,097,000 after buying an additional 60,849 shares during the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.